2014.~2016. 8.차의과학대학교 부속 구미차병원 조교수

학회 및 학술활동
대한간학회 정회원, 학술위원, 교육위원
대한임상초음파학회, 평생회원, 간행이사
대한간암학회 평생회원
대한소화기학회 평생회원
대한소화기내시경학회 평생회원
유럽간학회(EASL) 회원
아시안태평양간학회(APASL) 회원

발표 논문 (주저자)
1. Isolated Double-Chambered Right Ventricle in a Young Adult. The Korean Society of Cardiology 2001;41:272-275
2. Endoscopic Management of Rectal Dieulafoy’s lesion: A Case Series and Optimal Treatment. Clin Endosc. 2014;47(4):362-366.
3. Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy. World J Gastroenterol 2015;21(8):2568-2572
4. Severe fever with thrombocytopenia syndrome presenting as acute hepatic failure. Clin Exp Emerg Med 2015;2(2):1-4
5. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy. Clin Mol Hepatol 2015;21:242-248.
6. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. Clin Mol Hepatol 2015;21:287-294.
7. Successful Conservative Treatment of Spontaneous Perforated Duodenal Diverticulum: A Case Report. Korean J Helicobacter Up Gastrointest Res 2016;16:34-37.
8. Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease A Korean nationwide, multicenter, retrospective, observational, cohort study Medicine. (Baltimore). 2017;96(24):e6580
9. Early complications after percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1,843 ablations in 1,211 patients in a single centre: experience over 10 years. Clin Radiol. 2017;72(8):692.e9-692.e15
10. Long‑term follow‑up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report. Oncol Lett. 2017;14:4853-4856
11. Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article. Medicine (Baltimore). 2018;97(17):e0611.
12. Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B. Dig Liver Dis. 2018;50(6):628-630.
13. Cholestatic Jaundice as a Paraneoplastic Manifestation of Prostate Cancer Aggravated by Steroid Therapy. Med Princ Pract. 2018;27(2):197-200.
14. Tenofovir disoproxil fumarate-induced severe liver injury in a patient with chronic hepatitis B virus infection. Dig Liver Dis. 2018;50(6):628-630.
15. Simple Hepatic Cysts Mimicking Biliary Cystic Neoplasm after Ultrasound-Guided Percutaneous Alcohol Sclerotherapy. Clinical Ultrasound 2018; 3(2): 74-78.
16. Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease. Medicine (Baltimore) 2019;98(6):e14139).
17. Association of low skeletal muscle mass with advanced liver fibrosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2019;34(9):1633-1640.
18. Anti-nuclear antibody-negative immunoglobulin G4-associated autoimmune hepatitis mimicking lymphoproliferative disorders. Yeungnam Univ J Med. 2020;37(2):136-140
19. Effects of Branched-Chain Amino Acid (BCAA) Supplementation on the Progression of Advanced Liver Disease: A Korean Nationwide, Multicenter, Prospective, Observational, Cohort Study. Nutrients. 2020;5;12(5):E1429.
20. of the Long Noncoding RNA GAS5 Correlates With Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Genes. 2020;13;11(5):E545.
21. Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Yonsei Med J. 2020;61(10):860-867.
22. Plasma Long Noncoding RNA LeXis is a Potential Diagnostic Marker for Non-Alcoholic Steatohepatitis. Life (l). 2020;10(10):E230.
23. Fibrosis-4 index as a predictor for mortality in hospitalised patients with COVID-19: a retrospective multicentre cohort study. BMJ Open. 2020;10(11):e041989.
24. Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021;53(9):1030-1037.
25. Low Skeletal Muscle Mass Is a Risk Factor for Subclinical Atherosclerosis in Patients with Nonalcoholic Fatty Liver Disease. Diagnostics (l). 2021;11(5):854.
26. Association of Skeletal Muscle and Adipose Tissue Distribution with Histologic Severity of Non-Alcoholic Fatty Liver. Diagnostics (l). 2021;11(6):1061.
27. Long-term effects of the changes in hepatic steatosis status on the risk of incident type 2 diabetes mellitus: A 15-year community-d prospective cohort study. Diabetes Res Clin Pract. 2022;184:109208
28. Prognostic Impact of Myosteatosis on Mortality in Hospitalized Patients with COVID-19. Diagnostics (l). 2022;12(9):2255.
29. Performance of Simple Fibrosis Score in Non-Alcoholic Fatty Liver Disease with and without Type 2 Diabetes. Endocrinol b (Seoul), In press
30. Impact of bolic factors on risk of cardiovascular disease in nondiabetic bolic dysfunction-associated fatty liver disease. Hepatol Int. Acceptance